Company / SG&A Expense
AGIOS PHARMACEUTICALS, INC. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$180.3M
FY2025
5-year range
$115.1M / $180.3M
FY2021-FY2025
Trend
+15.0%
vs FY2024
Sector context
#78 of 213
Health Care
What the data says
At $180M, AGIOS PHARMACEUTICALS, INC.'s sg&a expense ranks #136 of 213 in the Health Care sector. SG&A Expense has increased for 3 consecutive years, from $115M in FY2022 to $180M in FY2025.
Based on SEC 10-K filings.
$180M in FY2025 with a 5-year CAGR of +9.6%.
Increased from $120M to $180M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +16.1%
- 5-Year CAGR
- +9.6%
- 10-Year CAGR
- -
Sector benchmark
#136 of 213 in Health CareTop 63% of 213This company $180.3M Sector average $722.3M
▼
-75.0% below sector average
Key checks
Key Insights
- AGIOS PHARMACEUTICALS, INC.'s sg&a expense has grown for 3 consecutive years.
- 5-year CAGR of +9.6%, indicating consistent growth.
- In FY2025, sg&a expense increased 15.0% year-over-year.
- Ranks #78 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.83 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $180.3M | +15.0% |
| FY2024 | $156.8M | +30.8% |
| FY2023 | $119.9M | +4.2% |
| FY2022 | $115.1M | -5.2% |
| FY2021 | $121.4M | +6.4% |
| FY2020 | $114.1M | +11.9% |
| FY2019 | $102.0M | +101.1% |
| FY2018 | $50.7M | -28.7% |
| FY2017 | $71.1M | +40.2% |
| FY2016 | $50.7M | +410.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026